|Awarded On||September 14, 2022|
|Title||Restoration of phagocytosis function of glioma-associated microglia/macrophage by activating QKI-PPARb-RXRa|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Jian Hu|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
Glioblastoma (GBM) is the most frequent and deadliest primary brain tumor. With the advent of immunotherapy, a number of cancers previously recalcitrant to all types of therapies have been successfully treated and even cured. Unfortunately, immunotherapy in its current form has not been shown to exert a clinical benefit for most GBM patients, probably due to unique composition and features of immune cells found in GBM. Due to certain defects in these immune cells, they have turned themselves from attackers of cancer cells to helpers of cancer cells. Our previous work has identified a class of important molecular regulators for these immune cells in GBM, and we have also found that two potent...